Know whether MIBG will work beforehand

What if you could tell whether MIBG would work for your child before therapy?

131 I-MIBG is a form of targeted "smart" radiation.  It continues to be one of the most effective treatments for children with relapsed neuroblastoma.  There are new studies to see if it works as well for upfront neuroblastoma therapy.  One of the major problems with radiation therapy are the side effects.  Unfortunately, while radiation may kill the tumor cells, radiation also effects healthy cells and causes side effects.  This research project is about studying patients who receive MIBG therapy to identify tests that can predict which children will ultimately benefit from MIBG therapy.  By completing this study we will be better able to predict if children with neuroblastoma will respond from this therapy or whether they should spare the side effects and try something more likely to work.

This study will evaluate a panel of DNA and RNA biomarkers in tumor and blood samples to determine which ones accurately identify groups of patients most likely to benefit from 131 I-MIBG.


Make smarter decisions from our tumor DNA

What if you knew whether a drug was working with a blood test?

One of the scariest times for a parent of a child with neuroblastoma is identifying whether a particular therapy is working or not. Therapy for neuroblastoma is often toxic with serious side effects. Furthermore, Why would you want to continue to subject a child to a therapy if it wasn't working?

Recently, a powerful new technology has been developed that allows researchers to detect small fragments of circulating tumor DNA (ctDNA) in the blood that has been released by cancer cells. Evaluating the ctDNA can provide an indication of how a patient is responding to treatment, since the amount of ctDNA released into the blood decreases as patients are responding and then increases when patients stop responding.  Additionally, the types of mutations seen in the ctDNA can help us understand how cancers change over time without having to do multiple invasive biopsies of tumors.  

Small studies have shown that ctDNA can be detected in patients with neuroblastoma, but this study, ANBL1531, provides an opportunity to look at this new tool over time in a large group of patients treated with and without 131I-MIBG.  Blood samples will be obtained diagnosis and then at designated times throughout therapy.  We will then determine how much ctDNA is present and what types of mutations are seen at each time point, and results correlated will be correlated with type of treatment (131I-MIBG or no 131I-MIBG) and with outcome.

This study will measure the ctDNA released by neuroblastoma cells into the blood during treatment with and without 131I-MIBG to find out how the 131I-MIBG is working